New trial
MATCHPOINT - Combined Immunotherapy for Relapsed/Progressive Medulloblastoma
- Trial ID
- NCT06514898 on ClinicalTrials.gov
- Cancer type
- Brain & CNS Tumors
- Published in
- New in Oncology - May 14, 2025
University of Florida is piloting a novel immunotherapy approach for children and young adults with relapsed/progressive medulloblastoma (Group 3/4) by combining adoptive cellular therapy (ex vivo expanded tumor-reactive lymphocytes and autologous hematopoietic stem cells), tumor RNA-pulsed dendritic cell vaccines, and PD-1 blockade with pembrolizumab.
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma